Despite being less common than other forms of cardiac amyloidosis, Apo AI amyloidosis and Apo AIV amyloidosis often deserve diagnostic consideration, according to these investigators.

124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the ...

Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with ...

Reassessing Cardiac Amyloidosis: Sex Disparities in Diagnostic Thresholds —Recent findings challenge the traditional view of cardiac amyloidosis as predominantly a male disease, indicating ...

The document provides a diagnostic algorithm and emphasizes the need for a ... The 51-page consensus document on cardiac amyloidosis was published online January 23 in the Journal of the American ...

Patients with cardiac amyloidosis have very poor survival without therapy. Diagnosis at early stages of the disease is crucial and there are many diagnostic tools for cardiac amyloidosis ...

Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment.

Recent studies have significantly enhanced the diagnostic accuracy for cardiac amyloidosis through innovative imaging techniques and artificial intelligence. In particular, ...

And then for AL amyloidosis, because it can affect almost any organ with the cardiac and kidney being common, it’s important to look at a noncardiac organ disfunction, like chronic kidney ...

The cardiac amyloidosis diagnostic algorithm should always begin with a monoclonal protein screen to assess for the presence of a plasma cell disorder and, therefore, supportive evidence for AL-CM ...

BURLINGAME, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic ...

Phase 3 - REVEAL study for iodine 124 I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women's Hospital, Boston MA, in conjunction with Attralus ...